Please upgrade your browser.
A phase II clinical trial of ixabepilone , an epothilone B analog, in patients with metastatic renal cell carcinoma
This phase II study was conducted to assess the efficacy and safety of ixabepilone in patients with metastatic renal cell carcinoma. Ixabepilone can cause tumor regression in some patients with metastatic renal cell carcinoma and could be considered in combination regimens with other therapies.
Psoriasis is thought to be angiogenesis dependent. Clear cell renal cell carcinoma is a hypervascularized solid tumor associated with loss of function of the von Hippel_Lindau (VHL) tumor suppressor.
The field of RCC biology continues to rapidly change. As new targeted strategies to control this cancer evolve, so do both the clinical strategies, and the strategies to measure response and predict outcome.
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: Comparison with the Memorial Sloan-Kettering prognostic factors model
The treatment paradigm in advanced renal cell carcinoma (RCC) has changed in the recent years. Sunitinib has been established as a new standard for first-line therapy. We studied the prognostic significance of baseline characteristics and we compared the risk stratification with the established Memorial Sloan Kettering Cancer Center (MSKCC) model. Studies on risk stratification of patients with advanced RCC treated with targeted therapies are warranted. Our results suggest that a simpler than the MSKCC model can be developed.
Data detailed in 'Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients' have been presented. According to recent research from Yamagata, Japan, "Incidence rate of renal cell carcinoma (RCC) differs among countries. The rates of Asian countries are lower than those of countries in North America or Europe but are exceptionally high in Japanese males."
Low serum sodium has recently been associated with poor survival in localised renal cell carcinoma (RCC). We now show the prognostic effect of serum sodium in patients with metastatic RCC (mRCC).
From Patton-Boggs, LLP: In a recent interview, Senate Majority Leader Harry Reid (D-NV) opened the door to using the budget reconciliation process as a means to secure enactment of health care reform legislation, predicting that such legislation will be done in the next 60 days.
If you (or someone you know) has metastatic cancer of the lung, prostate, colon, rectum, kidney, pancreas or malignant melanoma that is not responding to standard treatments, you may be able to participate in our clinical trial designed to evaluate the safety of a new type of cell therapy. Specifically, we are testing the safety and tolerability of the infusion of a type of your own white blood cells called NK cells.
|Powered by NeonCRM|